...musculoskeletal field and exclude dental and maxillofacial indications. Separately, DePuy AcroMed acquired the assets of Orquest...
...bone graft harvesting. DePuy plans to combine Healos with MP52. Biopharm GmbH , Heidelberg, Germany Orquest Inc....

...SMEN launched Orquest's Healos Bone Graft Substitute in the EU. Healos, a synthetic autograft substitute made...
...minerals, is used to decrease surgical time and post-operative complications associated with spine fusion surgery. Orquest Inc....

...fracture, dental and cartilage repair. Biopharm will contribute its MP52 recombinant BMP growth factor, and Orquest...
...growth factors and matrices. The companies previously agreed to develop HealosMP52 for spinal fusion with Orquest...
...partner Sulzer Spine-Tech (Minneapolis, Minn.) (see BioCentury, Oct. 4, 1999). Biopharm GmbH , Heidelberg, Germany Orquest Inc....

...Biopharm and Orquest will develop Healos/MP52, a bone growth factor product to treat spinal disorders. The...
...spinal disorders. The product will be based on Biopharm's MP52 recombinant bone inducing cytokine and Orquest's...
...from Sulzer Spine-Tech and will manufacture the product for Sulzer. Biopharm GmbH , Heidelberg, Germany Orquest Inc....

...grafting techniques. Data were presented at the North American Spine Society meeting in San Francisco. Orquest Inc....

...The product is in performance clinical trials in Europe and feasibility testing in the U.S. Orquest Inc....

...development of materials to help regenerate the cartilage on the surface of bones at joints. Orquest Inc....